HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Expression of CYP3A4 as a predictor of response to chemotherapy in peripheral T-cell lymphomas.

Abstract
Peripheral T-cell lymphomas (PTCLs) are aggressive tumors in which the current therapy based on multiagent chemotherapy is not successful. Since cytochrome P450 3A subfamily (CYP3A) enzymes are involved in the inactivation of chemotherapy drugs, we hypothesized that CYP3A and P-glycoprotein (MDR1) expression in these lymphomas could result in a poor clinical response. We measured tumoral CYP3A and MDR1 mRNA content in 44 T-cell lymphomas, finding a large variation in CYP3A expression. Multiplex polymerase chain reaction (PCR) analysis and fluorescence in situ hybridization (FISH) analysis showed genomic gains affecting CYP3A and MDR1 genes in T-cell lines and primary tumors, suggesting that this could be the mechanism underlying the tumoral expression variation. To test whether the tumoral expression of CYP3A and/or MDR1 could influence PTCL treatment outcome, their expression levels were compared with the clinical response and survival of the patients, finding that a high tumoral expression of CYP3A4 was significantly associated with a lower complete remission rate. This was further investigated with cell lines stably expressing CYP3A4 that exhibited an increased resistance to doxorubicin and etoposide. In conclusion, a high CYP3A4 tumoral expression could be useful to predict poor response to the standard PTCL chemotherapy; in these cases alternative chemotherapy combinations or doses should be explored.
AuthorsCristina Rodríguez-Antona, Susanna Leskelä, Magdalena Zajac, Marta Cuadros, Javier Alvés, Maria Victoria Moneo, Carmen Martín, Juan Cruz Cigudosa, Amancio Carnero, Mercedes Robledo, Javier Benitez, Beatriz Martínez-Delgado
JournalBlood (Blood) Vol. 110 Issue 9 Pg. 3345-51 (Nov 01 2007) ISSN: 0006-4971 [Print] United States
PMID17634410 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • ABCB1 protein, human
  • ATP Binding Cassette Transporter, Subfamily B
  • ATP Binding Cassette Transporter, Subfamily B, Member 1
  • Antineoplastic Agents
  • Etoposide
  • Doxorubicin
  • Cytochrome P-450 Enzyme System
  • Cytochrome P-450 CYP3A
  • CYP3A4 protein, human
Topics
  • ATP Binding Cassette Transporter, Subfamily B
  • ATP Binding Cassette Transporter, Subfamily B, Member 1 (genetics)
  • Antineoplastic Agents (therapeutic use)
  • Chromosomes, Human, Pair 7
  • Cytochrome P-450 CYP3A
  • Cytochrome P-450 Enzyme System (genetics)
  • Doxorubicin (therapeutic use)
  • Drug Resistance, Neoplasm (genetics)
  • Etoposide (therapeutic use)
  • Gene Duplication
  • Gene Expression
  • Gene Expression Regulation, Neoplastic
  • Humans
  • Jurkat Cells
  • Lymphoma, T-Cell, Peripheral (diagnosis, drug therapy, genetics, mortality)
  • Prognosis
  • Survival Analysis
  • Treatment Outcome
  • Tumor Cells, Cultured

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: